-
A Breakthrough for Alexander Disease: FDA Approves Zilganersen (Zanvastro)
NASDAQ: $IONS A New Horizon for Patients The FDA has officially granted approval for Zanvastro (zilganersen), a significant milestone for individuals living with Alexander disease (AxD). This rare, progressive, and fatal neurological disorder has long lacked targeted treatment options, making this approval a vital step forward for the medical community and patient families. Understanding Alexander…
-
A New Milestone in Rare Disease: FDA Approves Zilganersen (Zanvastro) for Alexander Disease
NASDAQ: $IONS A Breakthrough for Alexander Disease Patients The landscape for treating ultra-rare genetic disorders has shifted forward. The FDA has officially granted approval for Zanvastro (zilganersen), a pioneering treatment specifically indicated for patients living with Alexander disease (AxD). This approval represents a significant step forward for the medical community and, most importantly, for families…